RVMD - Revolution Medicines, Inc.

QQQ $ 468.68 $ 0.00 (0 %)

DIA $ 409.73 $ 1.01 (0.25 %)

SPY $ 555.67 $ 0.00 (0 %)

TLT $ 100.61 $ -0.08 (-0.08 %)

GLD $ 232.25 $ -0.37 (-0.16 %)

Previous Close

$ 41.66

Open

Bid

$ 41.66 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 15.44 - $ 48.61

Volume

406,011

Average Volume

Market Cap

6.96B

Beta (5Y Monthly)

$ 0.94

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-26-2024	12-31-2023	10-K
4	11-06-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	02-27-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-11-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	03-02-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-14-2020	03-31-2020	10-Q
19	03-30-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Revo...
08/12/2024 11:32:26

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $56 pric...

JP Morgan Maintains Overweight on Revoluti...
08/08/2024 16:25:57

JP Morgan analyst Eric Joseph maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target fro...

Wedbush Reiterates Outperform on Revolutio...
08/08/2024 13:16:12

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $59 price target.

Needham Maintains Buy on Revolution Medici...
08/08/2024 09:58:21

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.

Revolution Medicines Q2 2024 GAAP EPS $(0....
08/07/2024 21:25:25

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate o...

Barclays Maintains Overweight on Revolutio...
07/18/2024 15:38:39

Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target fro...

Oppenheimer Maintains Outperform on Revolu...
07/16/2024 12:47:17

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target fro...

B of A Securities Maintains Buy on Revolut...
07/16/2024 12:38:58

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target...

top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter

Top 3 Health Care Stocks That Should Keep ...
07/16/2024 12:16:01

microsoft-to-rally-around-6-here-are-10-top-analyst-forecasts-for-tuesday

Microsoft To Rally Around 6%? Here Are 10 ...
07/16/2024 12:05:43

HC Wainwright & Co. Maintains Buy on Revol...
07/16/2024 11:50:00

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...

Needham Maintains Buy on Revolution Medici...
07/16/2024 11:28:10

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.

Barclays Initiates Coverage On Revolution ...
07/12/2024 12:33:22

Barclays analyst Peter Lawson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announce...

$revolution-medicines-announces-publication-in-cancer-discovery-demonstrating-robust-anti-tumor-activity-of-rason-inhibitors-in-preclinical-models-of-refractory-kras-mutated-non-small-cell-lung-cancer$

Revolution Medicines Announces Publication...
07/11/2024 16:07:24

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activit...

why-helen-of-troy-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Helen of Troy Shares Are Trading Lower...
07/09/2024 16:59:31

nvidia-micron-arlo-technologies-and-other-big-stocks-moving-higher-on-tuesday

Nvidia, Micron, Arlo Technologies And Othe...
07/09/2024 14:05:05

Revolution Medicines To Provide Update On ...
07/08/2024 20:09:11

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS...

Jefferies Initiates Coverage On Revolution...
07/08/2024 12:59:57

Jefferies initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $63.

HC Wainwright & Co. Reiterates Buy on Revo...
05/13/2024 10:33:17

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 pric...

Wedbush Maintains Outperform on Revolution...
05/09/2024 12:47:33

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...